48 search results for: expert insights
World Congress of Dermatology (WCD) 2023 | Singapore
Highlights from the ADVENT symposium at the 2023 World Congress of Dermatology in Singapore.
ADVENT On Air | First-hand Experience: Practical Insights On the Diagnosis and Assessment of Atopic Dermatitis of the Hands and Feet
This podcast episode discusses best practices for the diagnosis of atopic dermatitis of the hands and feet
World Anosmia Day 2026
Join the effort to improve CRSwNP care. World Anosmia Day serves as an opportunity to raise awareness about the loss of the sense of smell. Access some of countless educational resources with ADVENT below.
The Role of Type 2 Inflammation in Moderate-to-Severe AD
In this expert interview video focusing on topics from the September 2024 ADVENT symposium at EADV’s Annual Meeting in Amsterdam, the Netherlands, Dr. Stephan Weidinger discusses how type 2 inflammation contributes to the systemic inflammation seen in patients with moderate-to-severe AD.
Early Intervention and the Potential For Disease Modification in AD
In this expert interview video focusing on topics from the September 2024 ADVENT symposium at EADV’s Annual Meeting in Amsterdam, the Netherlands, Dr. Eric Simpson discusses key considerations for disease modification and the importance of early intervention in treating patients with AD.
Emerging Real-World Data on Advanced Systemic Therapies in AD
In this expert interview video focusing on topics from the September 2024 ADVENT symposium at EADV’s Annual Meeting in Amsterdam, the Netherlands, Dr. Marjolein de-Bruin Weller highlights findings from the latest real-world studies on the use of advanced systemic treatments in patients with AD.
What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP
The March 2025 ADVENT symposium in Orlando, Florida brought together 4 dermatology experts to explore the evolving science of type 2 inflammation. Type 2 inflammation plays a central role in the pathophysiology of multiple dermatological diseases, driving chronic immune dysregulation that affects patients with atopic dermatitis (AD) prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP). Understanding the mechanisms behind type 2 inflammation is key to advancing care and improving patient quality of life.
ADVENT Forum 2025 On Demand page
Watch on-demand expert soundbites recorded at the April 2025 ADVENT Forum in Lisbon, Portugal, featuring dermatology and immunology perspectives on mechanisms and clinical practice. Topics range from disease mechanism to patient care and quality of life, spanning atopic dermatitis (AD), prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP).
ADVENT at ISDS 2023: Navigating Recent Scientific Advances in Atopic Dermatitis: Skin Barrier Dysfunction, Dysbiosis, and Itch
Highlights from the ADVENT symposium at the Inflammatory Skin Disease Summit (ISDS) 2023 exploring the role of type 2 inflammation in atopic dermatitis.
The Benefits of Early Intervention in AD: More Than Skin Deep
Many AD treatment goals focus on clinical manifestations, so that if a patient is free of lesions, their disease is considered well controlled. However, the inflammatory process underlying AD reaches far beyond the skin, affecting patients in unique ways at different stages of their lives. Education on the importance of treating AD beyond the skin and altering the treatment approach to fit the individual patient will help improve clinical management and reduce long-term patient burden.
Factors Associated With Development of Atopic Comorbidities in AD
Dr. Paller discusses factors influencing AD chronicity and comorbidities, focusing on disease severity, early onset, heredity, multiple allergies, and urban living as important in evaluating AD’s lasting effects on children.
Can Early Intervention Shape the Course of Atopic Dermatitis?
Dr. Paller presents highlights from recent clinical studies in AD, which highlight the potential benefits of early and effective AD treatment in modifying disease progression and mitigating atopic comorbidities.
